Literature DB >> 20649560

Guidelines for reporting experiments involving animals: the ARRIVE guidelines.

J C McGrath, G B Drummond, E M McLachlan, C Kilkenny, C L Wainwright.   

Abstract

British Journal of Pharmacology (BJP) is pleased to publish a new set of guidelines for reporting research involving animals, simultaneously with several other journals; the 'ARRIVE' guidelines (Animals in Research: Reporting In Vivo Experiments). This editorial summarizes the background to the guidelines, gives our view of their significance, considers aspects of specific relevance to pharmacology, re-states BJP's guidelines for authors on animal experiments and indicates our commitment to carrying on discussion of this important topic. We also invite feedback via the British Pharmacological Society website.

Mesh:

Year:  2010        PMID: 20649560      PMCID: PMC2936829          DOI: 10.1111/j.1476-5381.2010.00873.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  11 in total

Review 1.  The revised CONSORT statement for reporting randomized trials: explanation and elaboration.

Authors:  D G Altman; K F Schulz; D Moher; M Egger; F Davidoff; D Elbourne; P C Gøtzsche; T Lang
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

2.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.

Authors:  D Moher; K F Schulz; D G Altman
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

3.  Animal research: reporting in vivo experiments: the ARRIVE guidelines.

Authors:  Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  J Gene Med       Date:  2010-07       Impact factor: 4.565

4.  Reporting ethical matters in the Journal of Physiology: standards and advice.

Authors:  Gordon B Drummond
Journal:  J Physiol       Date:  2009-02-15       Impact factor: 5.182

5.  Improving the quality of reporting of randomized controlled trials. The CONSORT statement.

Authors:  C Begg; M Cho; S Eastwood; R Horton; D Moher; I Olkin; R Pitkin; D Rennie; K F Schulz; D Simel; D F Stroup
Journal:  JAMA       Date:  1996-08-28       Impact factor: 56.272

Review 6.  Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research.

Authors:  Carol Kilkenny; William J Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  PLoS Biol       Date:  2010-06-29       Impact factor: 8.029

7.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.

Authors:  Kenneth F Schulz; Douglas G Altman; David Moher
Journal:  BMJ       Date:  2010-03-23

8.  Less is more: reducing the reliance on animal models for nausea and vomiting research.

Authors:  V Robinson
Journal:  Br J Pharmacol       Date:  2009-07       Impact factor: 8.739

Review 9.  Opportunities for the replacement of animals in the study of nausea and vomiting.

Authors:  A M Holmes; J A Rudd; F D Tattersall; Q Aziz; P L R Andrews
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

10.  Survey of the quality of experimental design, statistical analysis and reporting of research using animals.

Authors:  Carol Kilkenny; Nick Parsons; Ed Kadyszewski; Michael F W Festing; Innes C Cuthill; Derek Fry; Jane Hutton; Douglas G Altman
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more
  1009 in total

1.  Inhibition of L-carnitine biosynthesis and transport by methyl-γ-butyrobetaine decreases fatty acid oxidation and protects against myocardial infarction.

Authors:  E Liepinsh; M Makrecka-Kuka; J Kuka; R Vilskersts; E Makarova; H Cirule; E Loza; D Lola; S Grinberga; O Pugovics; I Kalvins; M Dambrova
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

2.  Regulator of G-protein signalling 5 protects against atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Wen-Lin Cheng; Pi-Xiao Wang; Tao Wang; Yan Zhang; Cheng Du; Hongliang Li; Yong Ji
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

3.  The activation of supraspinal GPR40/FFA1 receptor signalling regulates the descending pain control system.

Authors:  K Nakamoto; T Nishinaka; N Sato; F Aizawa; T Yamashita; M Mankura; Y Koyama; F Kasuya; S Tokuyama
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

4.  FM19G11 reverses endothelial dysfunction in rat and human arteries through stimulation of the PI3K/Akt/eNOS pathway, independently of mTOR/HIF-1α activation.

Authors:  M El Assar; J M Sánchez-Puelles; I Royo; E López-Hernández; A Sánchez-Ferrer; J L Aceña; L Rodríguez-Mañas; J Angulo
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

5.  The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects.

Authors:  Maria Grazia Cascio; Erica Zamberletti; Pietro Marini; Daniela Parolaro; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2015-03       Impact factor: 8.739

6.  Novel Nrf2 activators from microbial transformation products inhibit blood-retinal barrier permeability in rabbits.

Authors:  Yasuhiro Nakagami; Kayoko Masuda; Emiko Hatano; Tatsuya Inoue; Takuya Matsuyama; Mayumi Iizuka; Yasunori Ono; Takashi Ohnuki; Yoko Murakami; Masaru Iwasaki; Kazuhiro Yoshida; Yuji Kasuya; Satoshi Komoriya
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

7.  The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.

Authors:  M Skinner; K Philp; D Lengel; L Coverley; E Lamm Bergström; P Glaves; H Musgrove; H Prior; M Braddock; R Huby; J O Curwen; P Duffy; A R Harmer
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

8.  Inhibition of inflammasome activation improves the impaired pattern of healing in genetically diabetic mice.

Authors:  Alessandra Bitto; Domenica Altavilla; Gabriele Pizzino; Natasha Irrera; Giovanni Pallio; Michele R Colonna; Francesco Squadrito
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

9.  Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats.

Authors:  Charles W Schindler; Eric B Thorndike; Bruce E Blough; Srihari R Tella; Steven R Goldberg; Michael H Baumann
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

10.  Antihyperalgesic effects of imidazoline I(2) receptor ligands in rat models of inflammatory and neuropathic pain.

Authors:  Jun-Xu Li; David A Thorn; Yanyan Qiu; Bi-Wen Peng; Yanan Zhang
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.